A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe by Lazarus JV et al.
Research Article
JOURNAL 
OF HEPATOLOGYA cross-sectional study of the public health response to
non-alcoholic fatty liver disease in EuropeGraphical abstracthttp://dx.doi.org/10.1016/j.jhep.2019.08.027
 2019 European Association for the Study of the Liver. Published by Elsevier B.V
license (http://creativecommons.org/licenses/by-nc-nd/4.0/). J. Hepatol. 2020, 72, 14AuthorsNO 100%
Does your country have any written
national NAFLD/NASH
strategy/action plan?
Highlights
 A comprehensive public health response to NAFLD is lacking
in the 29 countries.
 Major gaps include strategies, clinical guidelines, awareness
and education.
 Only 7 countries reported structured lifestyle programmes
aimed at NAFLD.
 Four countries reported active collaboration with civil soci-
ety groups on NAFLD issues.Jeffrey V. Lazarus, Mattias Ekstedt, Giulio
Marchesini, ..., Frank Tacke, Helena Cortez-
Pinto,Quentin M. Anstee
Correspondence
Jeffrey.Lazarus@ISGlobal.org
(J.V. Lazarus)
Lay summary
We conducted a survey on non-alcoholic
fatty liver disease with experts in Euro-
pean countries, coupled with data ex-
tracted from official documents on
policies, clinical guidelines, awareness,
and monitoring. We found a general lack
of national policies, awareness campaigns
and civil society involvement, and few
epidemiological registries.NAFLD and Alcohol-Related Liver Diseases. This is an open access article under the CC BY-NC-ND
–24
e
v
m
1
l
U
k
ti
se
iv
d
P
G
a,
h
io
and 7 (24%) reported structured lifestyle programmes aimed at
JOURNAL 
OF HEPATOLOGY
Research Article
NAFLD and Alcohol-Related Liver DiseasesA cross-sectional study of th
non-alcoholic fatty li
Jeffrey V. Lazarus1,⇑, Mattias Ekstedt2, Giulio
Juan M. Pericàs1,6, Elena Roel1,7, Manuel Ro
Helena Cortez-Pinto11,y, Quentin M. Anstee
Liver Foundation NAFLD Po
1Barcelona Institute for Global Health (ISGlobal), Hospital Clínic,
and Hepatology. Department of Medical and Health Sciences, Lin
Surgical Sciences, ‘‘Alma Mater” University, Bologna, Italy; 4EASL Interna
Ljubljana, Dept. of Gastroenterology, Slovenia; 6Translational Re
Diseases Clinical Direction, Biomedical Research Institute Dr Pifarré, Un
Hospital Clínic, Barcelona, Spain; 8UCM Digestive Diseases, ciberehd an
Spain; 9Pitie-Salpetriere Hospital, Department of Hepatology University
University Medical Center, Berlin, Germany; 11Departamento de
Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisbo
Newcastle University, Newcastle upon Tyne, United Kingdom; 13T
upon Tyne Hospitals NHS Foundat
Background & Aims: Non-alcoholic fatty liver disease (NAFLD)
is a growing public health problem worldwide and has become
an important field of biomedical inquiry. We aimed to deter-
mine whether European countries have mounted an adequate
public health response to NAFLD and non-alcoholic steatohep-
atitis (NASH).
Methods: In 2018 and 2019, NAFLD experts in 29 European
countries completed an English-language survey on policies,
guidelines, awareness, monitoring, diagnosis and clinical assess-
ment in their country. The data were compiled, quality checked
against existing official documents and reported descriptively.
Results: None of the 29 participating countries had written
strategies or action plans for NAFLD. Two countries (7%) had
mentions of NAFLD or NASH in related existing strategies (obe-
sity and alcohol). Ten (34%) reported having national clinical
guidelines specifically addressing NAFLD and, upon diagnosis,
all included recommendations for the assessment of diabetes
and liver cirrhosis. Eleven countries (38%) recommended
screening for NAFLD in all patients with either diabetes, obesity
and/or metabolic syndrome. Five countries (17%) had referral
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algorithms for follow-up and specialist referral in primary care,NAFLD. Seven (24%) had funded awareness campaigns that
specifically included prevention of liver disease. Four countries
(14%) reported having civil society groups which address NAFLD
and 3 countries (10%) had national registries that include
NAFLD.
Conclusions:We found that a comprehensive public health
response to NAFLD is lacking in the surveyed European coun-
tries. This includes policy in the form of a strategy, clinical
guidelines, awareness campaigns, civil society involvement,
and health systems organisation, including registries.
Lay summary:We conducted a survey on non-alcoholic fatty
liver disease with experts in European countries, coupled with
data extracted from official documents on policies, clinical
guidelines, awareness, and monitoring. We found a general lack
of national policies, awareness campaigns and civil society
involvement, and few epidemiological registries.
 2019 European Association for the Study of the Liver. Published by
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a growing challenge
to global public health. It is defined as the increased accumula-
tion of hepatic triglyceride (>5%) in the absence of excessive
alcohol consumption or other causes of liver disease. The NAFLD
spectrum encompasses steatosis (non-alcoholic fatty liver,
NAFL) and non-alcoholic steatohepatitis (NASH), an inflamma-
tory form of the condition marked by the presence of hepato-
cyte damage and progressive fibrosis that may lead to
cirrhosis.1,2 Although NAFLD may occur in patients with normal
weight, it is closely associated with the presence of the meta-
bolic syndrome, and therefore with obesity, type 2 diabetes020 vol. 72 j 14–24
mellitus, hypertension and dyslipidaemia.3 The prevalence
estimates of NAFLD vary widely according to the modality used
to detect NAFLD and the geographical area.3,4 Most of the larger
studies on NAFLD prevalence are based on ultrasonography,5
which is insensitive to modest increases in hepatic lipid accu-
mulation at levels <30%, and do not employ diagnostic tools rec-
ommended by current guidance (e.g. transient elastography,
NAFLD fibrosis score, magnetic resonance imaging, or the gold
standard, liver biopsy).1 Nevertheless, a recent meta-analysis
estimated the global prevalence of NAFLD to be 25%, with the
highest estimates in the Middle East and South America (32%
and 31%, respectively) and the lowest estimates in the African
continent (14%); the estimates for Asia, the USA, and Europe
were 27%, 24% and 23%, respectively.4
NAFLD is a cause of significant morbidity and mortality,
although it is not widely appreciated as being a major health
threat. NAFLD-related cirrhosis can result in end-stage liver dis-
ease and hepatocellular carcinoma (HCC).6,7 Recently, NAFLD
became one of the main causes of liver transplantation in the
United States.2,8,9 While this is not yet the case in Europe,
NAFLD is an increasingly common underlying cause of end-
stage liver disease, which contributes substantially to hospital
admissions.6,10 This difference in prevalence may, at least in
part, be due to an epidemiological lag in obesity rates in Europe
coupled with the potential lack of recognition of the disease in
European disease-coding data.11
Modelling studies predict a steady increase in the incidence
of NAFLD at the global level, accompanied by a proportionally
larger increase in NASH cases, liver transplantation, HCC and
mortality from liver and non-liver causes.4,12,13 This, combined
with the advent of highly efficacious antiviral agents against
hepatitis C, has contributed to the trend towards NAFLD becom-
ing the leading cause of liver transplantation in the near future.14
The economic burden associated with the NAFLD epidemic is
enormous and will continue to increase as societies become pro-
gressively affected by this global public health problem.15–17
To assess this growing public health threat, we aimed to deter-
mine the existence of policydocuments either specifically focused
on NAFLD/NASH or encompassing them in related disease/condi-
tionpolicies.Wealso aimed toexploreNAFLDawareness, and cap-
ture details of clinical guidelines for prevention, monitoring,
testing, diagnosis and treatment in European countries.
Patients and methods
Survey instrument
To design the survey instrument, the European Association for
the Study of the Liver (EASL) International Liver Foundation
(EILF) convened a study group of NAFLD experts at the first EASL
NAFLD Summit in November 2017. The survey instrument was
then revised through multiple rounds of feedback from the
study group over a 3-month period. The English-language 24-
item survey questionnaire had a mix of multiple choice and
open-ended questions and was grouped into 6 categories: (i)
policies/guidelines; (ii) continuing medical education and
awareness; (iii) monitoring and data; (iv) prevention, testing
and diagnosis; (v) clinical assessment; and (vi) treatment. This
questionnaire was piloted in 2018 with 8 countries (France,
Germany, Italy, Portugal, Slovenia, Spain, Sweden and the Uni-
ted Kingdom) and subsequently simplified into a 17-item ques-
tionnaire for the second phase of the study and employed with
all 29 participating countries.
Data collection and analysis
Data were collected from 29 countries: Norway, Switzerland
and all European Union countries expect for Malta. Data were
collected during late 2018 (pilot) and early 2019 (all countries).
Survey participants were recruited through a purposive sam-
pling process. A NAFLD expert was selected from each study
country. Each survey lead was tasked with completing a single
survey for their country. They received written guidance recom-
mending that they create an informal country-specific team of
up to 6 members (e.g. clinicians, government representatives,
and patient society representatives) to assist them in complet-
ing the survey and, to the extent possible, drawing responses
from existing documentation.
After the surveys were completed, 2 of the authors per-
formed a quality check. Participants were then e-mailed to seek
clarification for inconsistent/unclear responses and to provide
documentation to support answers when possible. Data collec-
tion for all countries closed on June 2019.
The data were compiled and descriptively analysed using
Microsoft Excel. The results are presented in 6 sections: national
or regional strategies on NAFLD and other conditions; national
clinical guidelines for NAFLD and assessment of other condi-
tions; national clinical guidelines for conditions other than
NAFLD; NAFLD management; NAFLD awareness; monitoring
and data.
Results
National or regional strategies on NAFLD and other
conditions
None of the 29 participating countries had official national
strategies for NAFLD. Thirteen countries (45%) had written
national or regional strategies for obesity; 10 (34%) for alcohol;
12 (42%) for cardiovascular disease; 4 (14%) for liver disease; 15
(48%) for diabetes; and 14 (48%) for healthy habits/nutrition.
However, NAFLD was specified in only 2 obesity strategies and
in 1 alcohol strategy (Table 1).
National clinical guidelines for NAFLD and assessment of
other conditions
Ten countries (35%) had national clinical guidelines for NAFLD
(Table 2). Upon NAFLD diagnosis, all 10 included specific recom-
mendations for the assessment of diabetes and liver cirrhosis.
Almost all also included specific recommendations for the
assessment of hypertension, dyslipidaemia, levels of alcohol
use, cardiovascular disease and HCC (Table 3).
National clinical guidelines for conditions other than NAFLD
Almost all countries (n = 25, 86%) had national guidelines for
diabetes. The most common existing clinical guidelines were
for dyslipidaemia (n = 19, 65%), hypertension (n = 19, 65%) and
obesity (n = 18, 62%). There were guidelines for alcohol in 14
countries (48%), ischaemic heart disease in 13 (45%), liver trans-
plant in 11 (38%) and end-stage liver disease/cirrhosis in 7
(24%). NAFLD/NASH was specifically mentioned in approxi-
mately half of the existing guidelines for end-stage liver dis-
ease/cirrhosis and liver transplant, whereas for the other
conditions NAFLD/NASH was mentioned in a much smaller
number of existing guidelines (Table 2). Eleven countries
(38%) recommended screening for NAFLD in all patients with
either diabetes, obesity and/or metabolic syndrome (Not shown
in tables).
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Table 1. National or regional strategies for NAFLD/NASH, key diseases or conditions related to NAFLD/NASH and their inclusion of NAFLD/NASH.
NAFLD/
NASH
Obesity Alcohol Cardiovascular disease Liver disease Diabetes Healthy habits/
nutrition
Strategy Strategy NAFLD/
NASH*
Strategy NAFLD/
NASH*
Strategy NAFLD/
NASH*
Strategy NAFLD/
NASH*
Strategy NAFLD/
NASH*
Strategy NAFLD/
NASH*
Austria – m m m m m m – n.a. m m m m
Belgium – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Bulgaria – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Croatia – – n.a. – n.a. X – – n.a. X – – n.a.
Czech Republic – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Denmark – – n.a. – n.a. – n.a. – n.a. X – X –
Estonia – X** – X** – X – X** – X** – X** –
Finland – m m m m m m m m m m m m
France – X – X – – n.a. – n.a. m m m m
Germany – X – X – – n.a. – n.a. – n.a. X –
Greece – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Hungary – DK n.a. – n.a. DK n.a. – n.a. DK n.a. DK n.a.
Ireland – X – DK n.a. DK n.a. – n.a. X – X –
Italy – – n.a. – n.a. – n.a. – n.a. X – X –
Latvia – – n.a. DK n.a. DK n.a. X – – n.a. X –
Lithuania – X – X – X – – n.a. X – – n.a.
Luxembourg – X – – n.a. X – – n.a. X – – n.a.
Netherlands – X – – n.a. – n.a. – n.a. – n.a. – n.a.
Norway – X – X – X – – n.a. X – X –
Poland – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Portugal – X X X X X – – n.a. X – X –
Republic of Cyprus – – n.a. – n.a. – n.a. – n.a. – n.a. – n.a.
Romania – DK n.a. – n.a. X – X – DK n.a. DK n.a.
Slovakia – X – X – X – – n.a. X – X –
Slovenia – X – – n.a. X – – n.a. X – X –
Spain – X – X – X – – n.a. X m X –
Sweden – – n.a. X – X – – n.a. X – X –
Switzerland – – n.a. – n.a. – n.a. X – – n.a. X –
United Kingdom – X X X^ – X – – n.a. X – X –
Total of affirmative
answers (%)
0/0 (0%) 13/29
(43%)
2/13 (15%) 10/29
(34%)
1/10 (10%) 12/29
(42%)
0/12 (0%) 4/29
(14%)
0/4 (0%) 14/29
(48%)
0/14 (0%) 14/29
(48%)
0/14 (48%)
Notes: Possible answers include yes (X), no (–), do not know (DK) and missing value (m). n.a., not applicable; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
*Denotes specific inclusion of information or mention of NAFLD/NASH in the strategy.
**Denotes that the disease or condition does not have a specific strategy although it is covered in another wider strategy.
^Previously an alcohol strategy in place up to 2012 but now only a ‘‘Youth Alcohol Strategy” and some inclusion in crime strategy.
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Table 2. National clinical guidelines for NAFLD/NASH and related key diseases or conditions and their inclusion of NAFLD/NASH.
NAFLD/
NASH
Dyslipidaemia Obesity Diabetes Alcohol Hypertension Ischaemic heart
disease
End-stage liver
disease/cirrhosis
Liver transplant
Guideline Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Guideline NAFLD/
NASH*
Austria – *** m m m m m m m m m m m m m m m m
Belgium X X – – n.a. X – X – X – – n.a. – n.a. – n.a.
Bulgaria – *** – *** n.a. X – X – X X – *** n.a. – *** n.a. X X X X
Croatia – – n.a. – n.a. X – – n.a. X – – n.a. – n.a. – n.a.
Czech Republic X X – X X X – X – X – X – – n.a. X X
Denmark X X – X X X – X – X – X – X – DK n.a.
Estonia – *** X – X – X – X – X – X – – *** n.a. X X
Finland – ^ m m m m m m m m m m m m m m m m
France – X – X – X – X – X – X – X – X –
Germany X X – X X X – X – X – X – X – – ^ n.a.
Greece – ^ X – – n.a. X – – n.a. X – – n.a. – n.a. – n.a.
Hungary – X DK DK n.a. X DK – n.a. X DK DK n.a. – n.a. – *** n.a.
– – – n.a. – n.a.
X – X X X X
n.a. – *** n.a. – ^ n.a.
– – – n.a. X –
– n.a. – n.a. – n.a.
– – – n.a. – n.a.
X – – n.a. X –
– n.a. – n.a. – n.a.
– – – n.a. X –
a. n.a. – n.a. – n.a.
a. n.a. X X – n.a.
a. n.a. – *** n.a. – *** n.a.
a. n.a. – n.a. – n.a.
– n.a. – n.a. X X
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17Ireland – – n.a. X
Italy X – n.a. X**
Latvia – – *** n.a. m m
Lithuania – X – X
Luxembourg – X – X
Netherlands – X – X
Norway – – n.a. X
Poland X X – X
Portugal – X – X
Republic of Cyprus – – n.a. – n.
Romania X X X DK n.
Slovakia X X – – *** n.
Slovenia – X – – n.
Spain X – n.a. X
Sweden – X** – X** – – – n.a. X –
– n.a. – n.a. – n.a.
X X X X X X
8
)
1/13
(8%)
7/29
(24%)
4/7
(57%)
11/29
(38%)
6/11
(55%)
al holic steatohepatitis.
at JOSwitzerland – X – X
United Kingdom X X X X
Total of
affirmative
answers (%)
10/29
(35%)
19/29
(66%)
2/19
(11%)
18/29
(62%)
6/1
(33%
Notes: Possible answers include yes (X), no (–), do not know (DK) and missing v
*Denotes specific inclusion of information or mention of NAFLD/NASH in the str
**Denotes that the disease or condition does not have a specific national guideline O
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^Denotes a clinical guideline being in development.X – X – X – X
X X X – – n.a. X
m m m m m m – ***
X – – n.a. X – X
X – – n.a. X – –
X – X – X – X
X X X – X – X
DK n.a. – n.a. DK n.a. –
X – X – X – X
X – – n.a. – n.a. –
X – DK n.a. X – DK
X – DK n.a. – *** n.a. – ***
X – – n.a. X – –
X – – n.a. – n.a. –
X – X – – n.a. X
X – DK n.a. X – –
X – X – X – X
25/29
(86%)
2/25
(8%)
14/29
(48%)
1/14
(7%)
19/29
(66%)
0/19
(0%)
13/29
(45%)
ue (m). n.a., not applicable; NAFLD, non-alcoholic fatty liver disease; NASH, non-alco
egy.
although it is covered in another clinical guideline.
NAFLD management
The healthcare providers specifically managing NAFLD included
hepatologists (86% of the countries) and gastroenterologists
(83%); less frequently, primary care physicians (48%), internal
medicine physicians (45%) and multi-disciplinary teams (24%)
(Table 4). Primary healthcare providers were typically responsi-
ble for the care of obesity (76%), diabetes (72%), metabolic syn-
drome (72%) and harmful alcohol use (62%) (Not shown in
tables). Five countries (17%) had algorithms for NAFLD manage-
ment in primary care centres. Regarding treatment, 7 countries
(24%) had structured lifestyle programmes for patients with
NAFLD (Table 5).
NAFLD awareness
Seven countries (24%) had funded public health awareness cam-
paigns specifically including preventive aspects of liver disease.
Only France, the Netherlands, Portugal and Switzerland
reported having any in-country civil society group focused on
NAFLD (Table 5).
Monitoring and data
Three countries (10%) reported national disease registries that
include NAFLD. Although only 8 countries (28%) had national
or regional NAFLD cohorts, some reported having local cohorts
in university hospitals. Eight countries (28%) had conducted
population-based epidemiological studies on NAFLD in the past
5 years and 2 (7%) have ongoing nationwide epidemiological
studies to assess NAFLD prevalence (Table 5).
Discussion
Our study is the first to comprehensively review national poli-
cies and guidelines on NAFLD. Despite the high burden of
NAFLD, earlier studies have primarily focused on clinical
aspects, laboratory findings and molecular pathways leading
to liver fibrosis. Our results demonstrate that while clinical
guidelines are available and epidemiological studies have been
conducted in some European countries, policies and the
involvement of civil society, as well as nationwide campaigns
are limited or non-existent in most countries. This is of particu-
lar concern in light of the estimated prevalence of NAFLD in Eur-
ope of 23.7%.3
The absence of national or regional strategies addressing
NAFLD is probably the most worrying finding. This reflects
either a lack of appreciation of the high prevalence and potential
health economic impact of this condition or a lack of prioritisa-
tion of this growing public health problem by international and
national institutions, or both. There is also a dearth of high-
quality epidemiological and health economic data to support
decision-makers. For example, estimates of NAFLD were not
provided by the Global Burden of Disease studies until its
2017 causes of death study, and no disability-adjusted life years
(DALYs) were calculated for it.18
Despite the strong relationship between NAFLD and obesity,
diabetes and cardiovascular risk, and the existence of well-
established strategies addressing the latter in most countries,
there is a paucity of strategies or guidelines on NAFLD. This is
probably because its potential for severity and progression has
been recognised only recently.
In spite of the absence of national and regional government
strategies, EASL2 and countries such as Germany,19 Italy,20
Spain21 and the UK22 do have clinical guidelines addressing
NAFLD. However, the majority of these guidelines, either speci-
fic for NAFLD or for other conditions closely linked to NAFLD, do
not universally recommend key measures such as systematic
screening for NAFLD in patients with metabolic risk factors like
type 2 diabetes and obesity. Nor do they recognise metabolic
syndrome associated liver disease, i.e. NAFLD, as a potential con-
tributory factor for liver damage in harmful alcohol use.7 Impor-
tantly, they also do not call for assessment of the presence of
other metabolic conditions after a diagnosis of NAFLD.
Currently, risk factors that indicate a need to screen for
NAFLD remain poorly defined and recommendations are incon-
sistent. The current EASL/European Association for the Study of
Diabetes (EASD)/European Association for the Study of Obesity
(EASO) guidelines recommend screening in high-risk groups
where metabolic risk factors are present.2 The German19 and
UK22 guidelines, developed as a joint effort between different
specialists, do incorporate clear algorithms for NAFLD screening
in high-risk populations (e.g. those with type 2 diabetes and
obesity). In contrast, societies such as the American Association
for the Study of Liver Diseases (AASLD) do not recommend rou-
tine screening in high-risk groups from primary care (typically
understood as general practitioners [GPs]), diabetes or obesity
clinics, although they acknowledge that there should be a high
suspicion of NAFLD and NASH in patients with type 2 diabetes.
This lack of consensus regarding the efficacy and/or cost-
effectiveness of systematic NAFLD screening among patients
with metabolic syndrome conditions, e.g. obesity23 and dia-
betes,24 reduces the likelihood of recommendations being uni-
Table 3. National clinical guidelines recommending assessment of the following diseases and conditions in patients with NAFLD upon diagnosis.
Diabetes Hypertension Dyslipidaemia Cardiovascular
disease
Liver
cirrhosis
Hepatocellular
carcinoma
Levels of
alcohol use
Belgium X X X X X X X
Czech Republic X X X X X – X
Denmark X X X – X X X
Germany X X X X X X X
Italy X X X X X X X
Poland X – – – X X –
Romania X X X X X X X
Slovakia X X X X X X X
Spain X X X X X X X
United Kingdom X X X X X – X
Total of affirmative
answers (%)
10/10
(100%)
9/10 (90%) 9/10 (90%) 8/10 (80%) 10/10
(100%)
8/10 (80%) 9/10 (90%)
Notes: Possible answers include yes (X), no (–), do not know (DK) and missing value (m). n.a., not applicable; NAFLD, non-alcoholic fatty liver disease.
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Table 4. Most common healthcare providers typically responsible for the care of NAFLD.
Gastroenterology Internal
Medicine
Hepatology Primary
care
Multi-
disciplinary
team
Diabetologist Nutritionist Endocrinologist Cardiologist Department of
infectious diseases
Austria – X X X – – – – – –
Belgium X – X – – – – – – –
Bulgaria X X X X X – – – – –
Croatia X – X – – – – – – –
Czech Republic X X X – – – – – – –
Denmark X – X X – – – – – –
Estonia X X – X – – – – – –
Finland X – – X – – – – – –
France X – X – – – – – – –
Germany X X X X – X X – – –
Greece X X X – X – – – – –
Hungary X X X X – – – – – –
Ireland X – X – – – – – – –
Italy X X X – X – – – – –
Latvia – – X – – – – – – –
Lithuania X – X – – – – X X –
Luxembourg X X X – – – – – – –
Netherlands X X X – X – – – – –
Norway X – – X – – – – – –
Poland – – X – – – – – – X
Portugal X X X X X – – – – –
Republic of Cyprus X X X X – – – – – –
Romania X – X – – – – – – –
Slovakia X – X – – – – – – –
Slovenia – – X – – – – – – –
Spain X – X X – – – – – –
Sweden X – – X X – – – – –
Switzerland – X X X – X – – – –
United Kingdom X – X X X – – – – –
Total of affirmative
answers (%)
24/29 (83%) 13/29 (45%) 25/29
(86%)
14/29
(48%)
7/29 (24%) 2/29 (7%) 1/29 (3%) 1/29 (3%) 1/29 (3%) 1/29 (3%)
Notes: Possible answers include yes (X), no (–), do not know (DK) and missing value (m). n.a., not applicable; NAFLD, non-alcoholic fatty liver disease. JO
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Follow-up and
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algorithms in
primary care
Structured
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programmes
Governm
awareness cam
include an
‘‘li
Austria – –
Belgium X X
Bulgaria – –
Croatia – X
Czech
Republic
X X
Denmark X –
Estonia – –
Finland – –
France – –
Germany – X
Greece – –
Hungary DK X
Ireland – –
Italy – –
Latvia – –
Lithuania – –
Luxembourg – –
Netherlands – –
Norway DK –
Poland – –
Portugal – –
Republic of
Cyprus
– –
Romania – –
Slovakia X X
Slovenia – –
Spain – –
Sweden – –
Switzerland m DK
United
Kingdom
X X
Total of
affirmative
answers (%)
5/29 (17%) 7/29 (24%)
Notes: Possible answers include yes (X), no (–), do not know (DK) and missing
*Not national but deemed representative of the German population.
**UK Biobank: Not national but deemed representative of the UK.t funded
igns that
aspect of
r health”
In-country civil
society group
focused on
NAFLD
National disease
registry that
include NAFLD/
NASH
National or
regional
NAFLD/NASH
cohort
ep
as
incid
– – – –
– – – –
– – – –
X – – X
– – – –
– – – –
– – – –
– – – –
– X – –
– – – X
– – – –
X DK – DK
– – – –
– – – –
X – – DK
– – X –
X – – –
– X – X
– – – –
– – – –
– X X –
– – – –
– – – –
DK – – X
X – – –
X – X X
– – – X
X X – X
– – – X
/29 (24%) 4/29 (14%) 3/29 (10%) 8/29 (28%)
alue (m). n.a., not applicable; NAFLD, non-alcoholic fatty liver disease; NASH, non-al
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OF HEPATOLOGYformly included in clinical guidelines or consistently adopted
into practice by GPs. There is indeed already emerging evidence
that adherence to the guidelines in clinical practice is poor.25
Research efforts that identify the pathophysiological links and
epidemiological associations between NAFLD and other preva-
lent conditions such as type 2 diabetes, hypertension and dys-
lipidaemia in the European population may further elucidate
risk factors and stratifiers to guide NAFLD screening.
One argument against screening for NAFLD or NASH is the
lack of an effective pharmacological treatment specifically
licensed for these conditions. However, dietary and lifestyle
changes have a substantial impact on the natural course of
the disease: weight reduction can lead to the regression of
steatosis, steatohepatitis or even fibrosis.26 Even without
weight loss, healthier dietary habits, physical activity and avoid-
ing a sedentary lifestyle have metabolic as well as hepatic ben-
efits.27 There are data supporting tailored selection of
pharmaceutical agents for the treatment of associated meta-
bolic conditions that may have additional liver-directed bene-
fits, for example, the use of pioglitazone or liraglutide to treat
type 2 diabetes may ameliorate coexistent NASH.9 Therefore,
not diagnosing NAFLD/NASH deprives patients of the opportu-
nity to address their risk of progressive liver disease in the con-
text of metabolic syndrome, of an opportunity to reinforce
dietary and lifestyle changes, and, most importantly, of proper
surveillance for liver-related complications in those that have
disease that has progressed to undiagnosed cirrhosis.
Although the occurrence of HCC in non-cirrhotic NASH is
well recognised, studies suggest that the individual risk of a
patient with non-cirrhotic NAFLD developing HCC remains
important aspects to focus on is modifying risk factors: to pre-
young people,41 with an estimated prevalence of 6–10%. As the
EAT-Lancet Commission reported recently,42 overweight andmodest, irrespective of the presence of type 2 diabetes.7,28 At
present, there are no data to support a recommendation for rou-
tine HCC surveillance in the non-cirrhotic NAFLD popula-
tion.29,30 However, half of the participating countries did
recommend an initial screen for HCC among patients when first
diagnosed with NAFLD/NASH. Identifying effective diagnostic
and prognostic biomarkers, such as markers for the risk of pro-
gression to HCC,31 would help to underpin strategic plans to
prevent and control NAFLD-related HCC.7
Our study found that hepatogastroenterologists were the
main healthcare providers in charge of managing patients with
NAFLD. However, the absence in most of the countries of algo-
rithms for follow-up and specialist referral, as well as of struc-
tured lifestyle programmes, reflects important gaps in NAFLD
management. Additionally, on average, awareness of NAFLD is
32–34poor among GPs, gastroenterologists and other clinicians.
This lack of awareness, in conjunction with the dearth of
national strategies and guidelines, leads to the underdiagnosis
of NAFLD.35 Therefore, continuing education programmes and
awareness campaigns are pivotal, as well as development and
adaptation of clinical guidelines to protocols to identify patients
who need specialist referral. Potential factors that need to be
assessed in further studies are the role of non-liver specialists,
including GPs, and the implementation of community-based
initiatives and civil society involvement aimed at NAFLD educa-
tion, prevention, detection and care (e.g. through community-
based participatory research study designs).
The dearth of algorithms for primary care referral is particu-
larly concerning in view of the high prevalence of NAFLD in Eur-
ope. Primary care should play a key role in the management of
NAFLD, not only because of its pivotal role in health promotion
and community care but also because specialised liver care isJournal of Hepatologynot prepared to receive such a large number of patients. Simple
and affordable algorithms to identify patients at high risk of
complications could be implemented in primary care to deter-
mine patients needing specialised care.36–38 This might con-
tribute to managing the complexity of the spectrum of
NAFLD-associated liver disease, including transplantation,
within a health system that ensures early detection and excel-
lent clinical management while maintaining economic sustain-
ability and equity.
Lack of government-supported surveillance systems to detect
andmonitor NAFLD and its associated comorbidities in the coun-
tries surveyed is another example of how limited commitment of
health authorities can influence the NAFLD response. This gap
was partially addressed by the academically led international
‘‘European NAFLD Registry” that was established in 2010 with
EASL and European Union funding to the Fatty Liver: Inhibition
of Progression (FLIP), Elucidating Pathways of Steatohepatitis (EPoS)
and Liver Investigation: Testing Marker Utility in Steatohepatitis
(LITMUS) research consortia. This registry was recruiting in sec-
ondary/tertiary care environments in some countries. However,
broadening the scope and geographical participation in this effort
to collect data on NAFLD/NASH across the general European pop-
ulationwould be beneficial. In the case of epidemiological knowl-
edge, the most urgent issue, together with the necessity of
implementing coordinated surveillance systems, is to comple-
ment the many studies providing highly valuable evidence on
the clinical aspects of NAFLD with studies addressing the social,
economic and cultural (including lifestyle) drivers of the epi-
demics. This might enable us to move from screening strategies
based on high-risk clinical profiles to a combination of genetic,
epidemiological and clinical profile approaches leading to
value-based care of patients with NAFLD.39
From a public health perspective, arguably one of the mostvent and reduce obesity rates and to achieve better dietary
habits.11 In the participating countries, the prevalence of phys-
ical inactivity is estimated to be 25–45% and obesity 20–30%.40
Childhood obesity is particularly worrying as NAFLD also affectsobesity rates are increasing globally, with 2.1 billion overweight
or obese individuals currently. Estimates place unhealthy diets
as the main contributor to the global burden of disease. Mea-
sures such as taxation, especially of sugar-sweetened bever-
ages,43 marketing regulation, improving nutritional labelling,
reformulating food, conducting awareness campaigns as well
as subsidies to increase consumption of healthier nourishment
have been proven to be successful in improving healthy eating
among the general population, including children.32,44 Also,
behavioural interventions that address both dietary habits and
exercise at an individual level are likely to reduce obesity
rates.45 One study estimated that reducing the consumption of
added sugars by 20% could prevent up to 770,000 DALYs due
to its impact on NAFLD (considering NASH, HCC and cirrhosis),
obesity, type 2 diabetes and coronary heart disease.46 Further,
structural changes in cities such as transportation policies
may contribute to increased physical activity.47
This study has several limitations. Although data were pro-
vided by leading in-country experts in consultation with col-
leagues, they were not externally validated, and some findings
may have been subject to interpretation, including when trans-
lating to English, or may have changed between data collection2020 vol. 72 j 14–24 21
Research Article NAFLD and Alcohol-Related Liver Diseasesand publication of the results. Nevertheless, as the overall study
findings were similar in all countries, i.e. the limited attention to
NAFLD in policies and practice, the data are consistent and plau-
sible. Future studies should seek to address additional countries
from around the world and also assess the economic burden and
implications for health system organisation of the increasing
prevalence of NAFLD in association with other conditions (e.g.
obesity and diabetes).
In conclusion, our study analysing the policies, guidelines,
health system organisation and epidemiological initiatives in
place for NAFLD in 29 European countries found that an
informed response was lacking. A comprehensive approach,
including formulating policy, developing clinical practice guide-
lines and conducting research is needed to effectively tackle
NAFLD in Europe. If the current growing prevalence of non-
communicable diseases is any indication, health systems should
turn their attention to NAFLD in order to raise awareness and
promote healthy lifestyles.
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